Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04027361 · ClinicalTrials.gov registry record · Phase 2
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04027361: Completed Phase 2 study, sponsored by Tris Pharma.
NCT04027361 is a Phase 2 study that has completed, run by Tris Pharma. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04027361, a Phase 2 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
Primary Outcome
Measurement of reaction time across a series of driving simulations
Interventions
- DRUG Amphetamine Extended Release (ER) Tablet 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 2 |
What the finished NCT04027361 record still lists
NCT04027361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Amphetamine Extended Release (ER) Tablet 20 mg is the first listed.
NCT04027361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04027361 about?
NCT04027361 is a clinical study titled "Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
What is the current status of trial NCT04027361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2019-10-01. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04027361?
The interventions under investigation include: Amphetamine Extended Release (ER) Tablet 20 mg (DRUG).
Who is sponsoring clinical trial NCT04027361?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04027361's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI